In 2020, the FDA granted its first approval to a comprehensive liquid biopsy, potentially representing a paradigm shift towards using liquid biopsies upfront as an easier, safer, faster, and more effective tool for diagnosing cancer patients than traditional invasive tissue…
Industry veteran Marine Queniart-Stojanovic, a self-described “global citizen with a French passport,” currently serves as Sanofi’s GM for general medicines in Thailand, Malaysia, and Singapore. With Sanofi undergoing a significant…
Singapore is one of the healthiest countries in Asia with a life expectancy in excess of 82 years buttressed by one of the most robust healthcare apparatuses in the world.…
The Asia-Pacific (APAC) region is home to around 1.44 billion people, over 60 percent of the world’s population, and a vast diversity of cultures, infrastructures, and economic development. Managing a…
Ashish Mahajan, Partner in Deloitte’s Life Sciences and Healthcare Consulting Practice in Southeast Asia, outlines some of the key trends playing out in the region, the extent to which the…
Professor Subra Suresh, president of Nanyang Technological University (NTU) and former director of the US National Science Foundation, explains how the university has managed to consistently be among the top…
Angeline Ho gives an overview of the patient advocacy landscape in Asia-Pacific, why an Asian model of patient engagement – distinct from those in Europe and the US – needs…
Writing in the December edition of DIA’s Global Forum magazine, Agnes Ho, Cindy Zen, and Tan Kwee Lan of Boehringer Ingelheim give an overview of the current regulatory framework for…
One of the main supporting pillars of Singapore’s pharmaceutical industry is its magnificent manufacturing base. Not only does the city-state rank as one of the few countries on the planet…
Since 2000, when Singapore first positioned biomedical research as the fourth pillar of the country’s economy, government funding towards innovative life sciences start-ups and spin-offs has dramatically increased. These companies…
Singapore recently outlined its latest Research, Innovation and Enterprise (RIE) 2025 plan, with plans to invest some USD 20 billion over the next 5 years. Here, three key stakeholders from…
To cater to Japan and Asia Pacific (JAPAC)’s booming biotech industry, in May 2021 IQVIA expanded its ‘IQVIA Biotech’ brand into the region. Looking ahead to 2022, IQVIA Biotech JAPAC…
Asia has experienced a biotech boom in the past five years. In 2020, almost 50 percent of the region’s clinical trials were led by biotechs and by 2025, biotech-led clinical…
See our Cookie Privacy Policy Here